Cargando…

Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status

Circulating phospholipids have been considered as biomarkers and therapeutic targets in multiple disorders. Atopic dermatitis (AD) is the most common inflammatory skin disease. Although there are numerous studies having addressed stratum corneum lipids in the context of epidermal barrier, little is...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, Takashi, Herrmann, Nadine, Maintz, Laura, Nümm, Tim Joachim, Welchowski, Thomas, Claus, Ralf A., Gräler, Markus H., Bieber, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844610/
https://www.ncbi.nlm.nih.gov/pubmed/35199091
http://dx.doi.org/10.1016/j.xjidi.2021.100092
_version_ 1784651514677035008
author Sakai, Takashi
Herrmann, Nadine
Maintz, Laura
Nümm, Tim Joachim
Welchowski, Thomas
Claus, Ralf A.
Gräler, Markus H.
Bieber, Thomas
author_facet Sakai, Takashi
Herrmann, Nadine
Maintz, Laura
Nümm, Tim Joachim
Welchowski, Thomas
Claus, Ralf A.
Gräler, Markus H.
Bieber, Thomas
author_sort Sakai, Takashi
collection PubMed
description Circulating phospholipids have been considered as biomarkers and therapeutic targets in multiple disorders. Atopic dermatitis (AD) is the most common inflammatory skin disease. Although there are numerous studies having addressed stratum corneum lipids in the context of epidermal barrier, little is known about the circulating lipids in patients with AD. In this study, we explored the changes of serum phospholipids in AD using liquid chromatography coupled to tandem mass spectrometry and sought serum lipids’ contribution to clinical status. Several serum levels of phospholipids were altered in the AD group (n = 179) compared with that in healthy controls (n = 47) and patients without AD with atopic comorbidities (n = 22); lipids exhibiting the apparent changes included increased sphingosine, multiple variants of phosphatidylcholine, and decreased ceramide (16:0) in patients with AD. Moreover, serum levels of sphingosine correlated with the severity of AD, and sphingosine and ceramide(16:0) were also detected as the risk-increasing effect and risk-reduction effect of AD, respectively. In summary, alterations in the serum concentration of phospholipids are seen in patients with AD. Although more detailed investigations will be needed to evaluate the significance of the changes in circulating lipids in AD, these findings can provide, to our knowledge, previously unreported insight into AD’s pathogenesis and therapeutic strategies.
format Online
Article
Text
id pubmed-8844610
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88446102022-02-22 Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status Sakai, Takashi Herrmann, Nadine Maintz, Laura Nümm, Tim Joachim Welchowski, Thomas Claus, Ralf A. Gräler, Markus H. Bieber, Thomas JID Innov Original Article Circulating phospholipids have been considered as biomarkers and therapeutic targets in multiple disorders. Atopic dermatitis (AD) is the most common inflammatory skin disease. Although there are numerous studies having addressed stratum corneum lipids in the context of epidermal barrier, little is known about the circulating lipids in patients with AD. In this study, we explored the changes of serum phospholipids in AD using liquid chromatography coupled to tandem mass spectrometry and sought serum lipids’ contribution to clinical status. Several serum levels of phospholipids were altered in the AD group (n = 179) compared with that in healthy controls (n = 47) and patients without AD with atopic comorbidities (n = 22); lipids exhibiting the apparent changes included increased sphingosine, multiple variants of phosphatidylcholine, and decreased ceramide (16:0) in patients with AD. Moreover, serum levels of sphingosine correlated with the severity of AD, and sphingosine and ceramide(16:0) were also detected as the risk-increasing effect and risk-reduction effect of AD, respectively. In summary, alterations in the serum concentration of phospholipids are seen in patients with AD. Although more detailed investigations will be needed to evaluate the significance of the changes in circulating lipids in AD, these findings can provide, to our knowledge, previously unreported insight into AD’s pathogenesis and therapeutic strategies. Elsevier 2021-12-22 /pmc/articles/PMC8844610/ /pubmed/35199091 http://dx.doi.org/10.1016/j.xjidi.2021.100092 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Article
Sakai, Takashi
Herrmann, Nadine
Maintz, Laura
Nümm, Tim Joachim
Welchowski, Thomas
Claus, Ralf A.
Gräler, Markus H.
Bieber, Thomas
Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status
title Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status
title_full Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status
title_fullStr Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status
title_full_unstemmed Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status
title_short Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status
title_sort altered serum phospholipids in atopic dermatitis and association with clinical status
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844610/
https://www.ncbi.nlm.nih.gov/pubmed/35199091
http://dx.doi.org/10.1016/j.xjidi.2021.100092
work_keys_str_mv AT sakaitakashi alteredserumphospholipidsinatopicdermatitisandassociationwithclinicalstatus
AT herrmannnadine alteredserumphospholipidsinatopicdermatitisandassociationwithclinicalstatus
AT maintzlaura alteredserumphospholipidsinatopicdermatitisandassociationwithclinicalstatus
AT nummtimjoachim alteredserumphospholipidsinatopicdermatitisandassociationwithclinicalstatus
AT welchowskithomas alteredserumphospholipidsinatopicdermatitisandassociationwithclinicalstatus
AT clausralfa alteredserumphospholipidsinatopicdermatitisandassociationwithclinicalstatus
AT gralermarkush alteredserumphospholipidsinatopicdermatitisandassociationwithclinicalstatus
AT bieberthomas alteredserumphospholipidsinatopicdermatitisandassociationwithclinicalstatus